- AZETIDINES AS EP2 ANTAGONISTS
-
The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids (leiomyomata)and to intermediates usefulin their synthesis and to compositions containing them.
- -
-
Page/Page column 54
(2009/06/27)
-
- Azetidines
-
The invention relates to EP2 antagonist azetidines of formula (I) wherein Ar, R1, X, and Z are as defined herein, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids, to intermediates useful in their synthesis, and to compositions containing them.
- -
-
Page/Page column 31
(2008/12/08)
-
- Concise synthesis of novel 2,6-diazaspiro[3.3]heptan-1-ones and their conversion into 2,6-diazaspiro[3.3]heptanes
-
A concise synthesis, amenable to library production of 2,6-diazaspiro[3.3] heptan-1-ones and their subsequent conversion into 2,6-diazaspiro[3.3]heptanes is reported. Georg Thieme Verlag Stuttgart.
- Stocks, Michael J.,Hamza, Daniel,Pairaudeau, Garry,Stonehouse, Jeffrey P.,Thorne, Philip V.
-
p. 2587 - 2589
(2008/02/13)
-
- A novel rearrangement reaction conversion of 3-(chloromethyl)azetidin-2-ones to azetidine-3-carboxylic acid esters
-
Transformation of 3-(chloromethyl)azetidin-2-ones to azetidine-3-carboxylic acid esters is described. The readily available 3-(chloromethyl)azetidin-2-ones rearranged in good yields to azetidine-3-carboxylic acid esters on treatment with alkoxides. An alternative ring opening - ring closure procedure is also identified.
- Bartholomew,Stocks
-
p. 4795 - 4798
(2007/10/02)
-